Published on
May 27, 2022

Psychedelic Headlines | May 27th

Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.


Performance of psychedelic public companies this past week.

Company News

COMPASS Pathways ($CMPS) provided positive data from the largest ever psilocybin study in treatment-resistant depression. The Phase IIb study showed that a single dose of psilocybin, in combination with psychological support, was associated with a highly statistically significant reduction in depressive symptoms after three weeks. Press Release

Clearmind Medicine ($CMND | $CMNDF) announced successful Pre-IND meeting with the FDA for CMND-100 as a potential treatment for alcohol use disorder. CMND-100 is Clearmind's lead product that is based on MEAI, a novel psychoactive compound. Press Release

Biomind Labs ($BMND | $BMNDF) received approval for a third Phase II clinical trial for their BMND08 candidate based on 5-MeO-DMT as a potential treatment for depression and anxiety in patients with Alzheimer’s-type cognitive impairment. Press Release

Optimi Health ($OPTI | $OPTHF) successfully completed their first harvest of psilocybin cubensis and functional mushrooms and entered into a supply agreement with Halucenex Life Sciences, a wholly owned subsidiary of Creso Pharma. Details

PharmaTher Holdings ($PHRM | $PHRRF) entered into a development agreement with CC Biotechnology, a leader in the design and manufacturing of wearable injectors, to create a proprietary wearable ketamine delivery device for mental health, neurological and pain disorders. Press Release

Ceruvia Lifesciences (Private) submitted an IND application to begin a Phase II clinical trial to determine the efficacy and safety of a single oral dose of synthetic psilocybin as a potential treatment for obsessive-compulsive disorder.Press Release

Tryp Therapeutics ($TRYP | $TRYPF) appointed Chris Ntoumenopoulos to their Board of Directors, to further support Tryp's mission of advancing the delivery of psychedelic medicines. Ntoumenopoulos has extensive experience in financial markets both in raising capital and corporate strategy. Press Release

Awakn Life Sciences ($AWKN | $AWKNF) filed a Patent Cooperation Treaty application for the treatment of behavioral addictions with ketamine and ketamine-assisted psychotherapy. The patent claims would give Awakn exclusive rights to use ketamine and ketamine-assisted therapy for the treatment of behavioral addictions. Press Release

Albert Labs ($ABRT) appointed Dr. Sara Tai, a Senior Lecturer in Clinical Psychology from Manchester University, as Principal Investigator for their upcoming trial. The trial will evaluate the safety and efficacy of KRN-101, a psilocybin-based medicine, for the treatment of cancer-related distress. Press Release

Mydecine Innovations Group ($MYCO | $MYCOF) closed their overnight marketed public offering, raising $2.8 million. Mydecine will use the new growth capital to support their clinical trials and partnerships. Press Release


Psychedelic Finance: Interview With Husch Blackwell Law Firm on Psychedelics & Emerging Therapies

Bloomberg: Psychedelic Therapy Retreats Target Corporate Executives

The New York Times: Female Veterans Turn to Psychedelic Therapy

UC Davis Health: $2.7M Grant To Find New Addiction Treatments Related To Psychedelics

Be the first to see new company features, exclusive interviews and breaking news in the psychedelic markets. Subscribe now.